Live Breaking News & Updates on Pathshodh Healthcare Pvt Ltd

Share
New Delhi: A Bangalore-based start-up has developed a novel, point-of-care Electrochemical ELISA test that enables fast and accurate estimation of total antibody concentration of COVID 19 in clinical samples.
PathShodh Healthcare, the start-up incubated at the Society for Innovation and Development (SID), Indian Institute of Science (IISc), has made a very significant breakthrough to develop the first of its kind, semi-quantitative Electrochemical ELISA test for COVID-19 IgM and IgG antibodies. While 
Qualitative
semiquantitative analysis gives an approximate 
estimation of their concentrations. PathShodh has received the license to manufacture for sale from the Central Drugs Standard Control Organisation (CDSCO), after validation at Translational Health Science and Technology Institute (THSTI), Faridabad, as per the requirements of Indian Council of Medical Research (ICMR). ....

Andhra Pradesh , New Delhi , Vinay Kumar , Ashutosh Sharma , Aarogya Setu , Centre For Augmenting , Centre For Nano Science , Division Of Interdisciplinary Sciences , Health Crisis , Translational Health Science , Indian Institute Of Science Iisc , Pathshodh Healthcare Pvt Ltd , Indian Council Of Medical Research , Founder Pathshodh Healthcare Pvt Ltd , Central Drugs Standard Control Organisation , Professor Centre For Nano Science , Society For Innovation , Department Of Science , Technology Institute , Shodh Healthcare , Indian Institute , Indian Council , Medical Research , Receptor Binding Domain , Navakanta Bhat , Interdisciplinary Sciences ,